Sone-214

: Try searching for "sone-214" on the internet. This might lead you to product pages, technical specifications, user manuals, or forums where people discuss the item.

If you meant something else by "sone-214" (a different industry code, a hardware part, a song, etc.), please provide more context, and I will be happy to correct the answer. sone-214

Without more context, I can also offer some general advice on guides and troubleshooting: : Try searching for "sone-214" on the internet

Sone-214 is a highly selective and potent inhibitor of the c-MET signaling pathway. By binding to the ATP-binding site of the c-MET receptor, Sone-214 effectively blocks the activation of downstream signaling pathways, thereby inhibiting the downstream effects of c-MET signaling. Specifically, Sone-214 has been shown to prevent the recruitment of p85 subunit of PI3K to c-MET, leading to a reduction in the activation of the PI3K/AKT signaling cascade and the subsequent suppression of cell growth and survival pathways. Without more context, I can also offer some

Sone-214 holds significant promise as a novel cancer therapy due to its distinct mechanism of action, which differentiates it from conventional chemotherapy agents. Potential benefits of Sone-214 include:

The c-MET signaling pathway is a key regulator of cellular growth, survival, and motility in response to its ligand, hepatocyte growth factor (HGF). Aberrant activation of c-MET has been implicated in the development and progression of numerous cancers, leading to tumor aggression, chemotherapy resistance, and poor patient outcomes. The c-MET pathway has also been linked to the epithelial-to-mesenchymal transition (EMT) process, which enables cancer cells to acquire migratory and invasive properties, further complicating cancer treatment.

| Aspect | Explanation | |--------|-------------| | | STING is a cytosolic DNA‑sensing adaptor that, when activated, drives production of IFN‑β and other cytokines. Tumor cells with low innate immune signaling (“cold” tumors) can be “heated” by STING activation, recruiting dendritic cells (DCs) and CD8⁺ T cells. | | Partial vs. full agonism | Full agonists (e.g., cyclic dinucleotides like cGAMP) produce strong NF‑κB activation → high systemic cytokine release (IL‑6, TNF‑α). SONE‑214 is engineered to bias signaling toward IRF3/7 → robust IFN‑β with a ≤ 30 % NF‑κB response in in‑vitro reporter assays. | | Pharmacokinetic (PK) advantages | • Oral bioavailability ≈ 45 % in rats (fasted). • Half‑life ≈ 6–8 h (mouse), enabling once‑daily dosing. • Minimal plasma protein binding (≈ 20 %). | | Selectivity | No significant activity (< 10 % of 50 µM) against a panel of 300 off‑target receptors/enzymes, including TLRs, NOD‑like receptors, and other innate‑immune sensors. | | Cellular read‑outs | • IFN‑β EC₅₀ ≈ 45 nM (human THP‑1 cells). • NF‑κB EC₅₀ ≈ 1 µM. • No detectable cytotoxicity up to 30 µM. |